As filed with the Securities and Exchange Commission on May 12, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
IN8BIO, INC.
(Exact name of registrant as specified in its charter)
Delaware | 82-5462585 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
350 5th Avenue, Suite 5330 New York, New York |
10118 | |
(Address of Principal Executive Offices) | (Zip Code) |
2020 Equity Incentive Plan
2020 Employee Stock Purchase Plan
(Full titles of the plans)
William Ho
President and Chief Executive Officer
IN8bio, Inc.
350 5th Avenue, Suite 5330, New York, New York 10118
(646) 600-6438
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Joshua A. Kaufman
Jaime L. Chase
Cooley LLP
55 Hudson Yards
New York, New York 10001
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large Accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Pursuant to General Instruction E of Form S-8, IN8bio, Inc. (the Registrant) is filing this Registration Statement with the Securities and Exchange Commission (the Commission) to register an additional 939,062 shares of common stock under the 2020 Equity Incentive Plan and an additional 187,812 shares of common stock under the 2020 Employee Stock Purchase Plan, pursuant to the provisions of each plan which provide for annual automatic increases in the number of shares of common stock reserved for issuance under each respective plan. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. | Incorporation of Documents by Reference. |
The Registrant hereby incorporates by reference into this Registration Statement the following documents filed by it with the Commission:
(a) | the contents of the Registrants Registration Statement on Form S-8, previously filed with the Commission on September 10, 2021 (File No. 333-259458); |
(b) | the Registrants Annual Report on Form 10-K (File No. 001-39692) for the fiscal year ended December 31, 2021, filed with the Commission on March 17, 2022; |
(c) | the Registrants Current Report on Form 8-K (File No. 001-39692), filed on March 28, 2022; |
(d) | the Registrants Quarterly Report on Form 10-Q (File No. 001-39692), filed on May 12, 2022; and |
(e) | the description of the Common Stock contained in the Registrants Registration Statement on Form 8-A (File No. 001-39692), filed with the Commission on November 10, 2020, under Section 12(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), including any amendments or reports filed for the purpose of updating such description. |
All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.
Item 8. | Exhibits. |
The exhibits to this Registration Statement are listed below:
* | Filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on May 12, 2022.
IN8bio, Inc. | ||
By: | /s/ William Ho | |
William Ho | ||
President and Chief Executive Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints William Ho and Patrick McCall, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date | ||
/s/ William Ho William Ho |
President, Chief Executive Officer and Director (Principal Executive Officer) |
May 12, 2022 | ||
/s/ Patrick McCall Patrick McCall |
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | May 12, 2022 | ||
/s/ Alan S. Roemer Alan S. Roemer |
Chairman of the Board of Directors | May 12, 2022 | ||
/s/ Peter Brandt Peter Brandt |
Director | May 12, 2022 | ||
/s/ Emily T. Fairbairn Emily T. Fairbairn |
Director | May 12, 2022 | ||
/s/ Luba Greenwood Luba Greenwood |
Director | May 12, 2022 | ||
/s/ Travis Whitfill Travis Whitfill |
Director | May 12, 2022 |
Exhibit 5.1
Joshua A. Kaufman T: +1 212 479 6495 josh.kaufman@cooley.com |
May 12, 2022
IN8bio, Inc.
350 5th Avenue
Suite 5330
New York, New York 10118
Ladies and Gentlemen:
We have represented IN8bio, Inc., a Delaware corporation (the Company), in connection with the filing by the Company of a registration statement on Form S-8 (the Registration Statement) with the Securities and Exchange Commission, covering the offering of up to 1,126,874 shares (the Shares) of the Companys common stock, par value $0.0001 per share (the Common Stock), consisting of (i) 939,062 shares of Common Stock issuable pursuant to the Companys 2020 Equity Incentive Plan (the 2020 Plan), and (iii) 187,812 shares of Common Stock issuable pursuant to the Companys 2020 Employee Stock Purchase Plan (together with the 2020 Plan, the Plans).
In connection with this opinion, we have examined and relied upon (i) the Registration Statement and related prospectuses, (ii) the Companys Amended and Restated Certificate of Incorporation, and Amended and Restated Bylaws, each as currently in effect, (iii) the Plans and (iv) originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery by all persons other than by the Company of all documents where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.
Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.
On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and related prospectuses, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).
Our opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. Our opinion is based on these laws as in effect on the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein.
Cooley LLP 55 Hudson Yards New York, NY 10001
t: (212) 479-6000 f: (212) 479-6275 cooley.com
|
May 12, 2022 Page Two |
We consent to the filing of this opinion as an exhibit to the Registration Statement.
Sincerely,
Cooley LLP
By: |
/s/ Joshua A. Kaufman | |
Joshua A. Kaufman |
Cooley LLP 55 Hudson Yards New York, NY 10001
t: (212) 479-6000 f: (212) 479-6275 cooley.com
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement on Form S-8 of IN8bio, Inc. of our report dated March 17, 2022, on our audits of the financial statements of IN8bio, Inc. as of December 31, 2021 and 2020 and for the years then ended, which report is included in IN8bio, Inc.s Annual Report on Form 10-K for the year ended December 31, 2021.
/s/ CohnReznick LLP
Tysons, Virginia
May 11, 2022
Exhibit 107
CALCULATION OF REGISTRATION FEE
Security Type |
Security Class Title | Fee Calculation Rule |
Amount Registered(1) |
Proposed Maximum Offering Price Per Share |
Maximum Aggregate Offering Price |
Fee Rate | Amount of Registration Fee | |||||||
Equity |
2020 Equity Incentive Plan (Common stock, $0.0001 par value per share) |
Other | 939,062(2) | $2.69(4) | $2,521,381.47 | .0000927 | $233.73 | |||||||
Equity |
2020 Employee Stock Purchase Plan (Common stock, $0.0001 par value per share) |
Other | 187,812(3) | $2.28(5) | $428,633.94 | .0000927 | $39.73 | |||||||
Total Offering Amounts |
$2,950,015.41 | $273.47 | ||||||||||||
Total Fees Previously Paid |
$273.47 | |||||||||||||
Total Fee Offsets |
| |||||||||||||
Net Fee Due |
|
(1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this Registration Statement shall also cover any additional shares of common stock that become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of IN8bio, Inc.s (the Registrant) outstanding shares of common stock, par value $0.0001 per share (the Common Stock). |
(2) | Represents additional shares of the Registrants Common Stock reserved for future grant under IN8bio, Inc. 2020 Equity Incentive Plan (the 2020 Plan) as a result of the automatic increase in shares reserved thereunder on January 1, 2022 pursuant to the terms of the 2020 Plan. The 2020 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2020 Plan on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (a) 5% of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year and (b) a number of shares of Common Stock designated by action of the Registrants board of directors. |
(3) | Represents additional shares of the Registrants Common Stock reserved for issuance under the IN8bio, Inc. 2020 Employee Stock Purchase Plan (the ESPP) as a result of the automatic increase in shares reserved thereunder on January 1, 2022 pursuant to the terms of the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1, 2022 through January 1, 2031. The number of shares added each year will be equal to the lesser of: (a) 1% of the total number of shares of Common Stock outstanding on the last day of the calendar month before the date of the automatic increase; (b) 400,000 shares of Common Stock and (c) a number of shares of Common Stock designated by action of the Registrants board of directors prior to the date of the increase. |
(4) | Estimated pursuant to Rules 457(c) and 457(h) solely for the purpose of calculating the registration fee. The proposed maximum offering price per share and proposed maximum aggregate offering price are based on the average of the high and low sale prices of the Common Stock as reported on The Nasdaq Global Market on May 10, 2022. |
(5) | Estimated pursuant to Rules 457(c) and 457(h) solely for the purpose of calculating the registration fee. The proposed maximum offering price per share and proposed maximum aggregate offering price are based on the average of the high and low sale prices of the Common Stock as reported on The Nasdaq Global Market on May 10, 2022 multiplied by 85%, which is the percentage of the price per share applicable to purchases under the ESPP. |